Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Michael R Migden, Carola Berkin, Anne Lynn Chang, Et Al.
2018 SKIN The Journal of Cutaneous Medicine  
not available. Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi. Copyright 2018 SKIN
doi:10.25251/skin.2.supp.77 fatcat:wbef6uljkzdodky3w4tipggffu